Lièvre A, Turpin A, Ray-Coquard I, et al. - Researchers sought the predictive factors for COVID-19 severity and mortality in cancer patients via a large nationwide retro-prospective cohort study of patients with solid tumors and COVID-19. They analyzed the data of 1,289 patients diagnosed between April 4 to June 11, 2020, of whom 424 (33%) patients had a severe form of COVID-19 and 370 (29%) patients died. Male gender, ECOG PS ≥ 2, updated Charlson comorbidity index, and admission to ICU are the factors independently linked with death in multivariate analysis. Recent anticancer treatments did not have any deleterious effects, other than cytotoxic chemotherapy in the RT-PCR-confirmed subgroup of patients. The systemic anticancer therapy was either interrupted or stopped after COVID-19 diagnosis in almost 40% of patients.